Long-fragment DNA as a potential marker for stool-based detection of colorectal cancer.

YIBO ZHANG,ISAO SAKAIDA,SHINGO HIGAKI,TAKAHIRO YAMASAKI,YOSHITARO SHINDO,SHOICHI HAZAMA,YUTAKA SUEHIRO,MASAAKI OKA,KOUHEI SAKAI

doi:10.3892/ol.2014.2632

YIBO ZHANG, ISAO SAKAIDA + Show 7 more

Open Access

https://doi.org/10.3892/ol.2014.2632

Copy DOI

Journal: Oncology letters	Publication Date: Oct 24, 2014
Citations: 6	License type: CC BY 3.0

Affiliation: Yamaguchi University

Abstract

Neoplastic cells that are exfoliated from the colorectal epithelium exhibit dysfunctional apoptotic mechanisms, and thus it is possible to identify high-molecular-weight DNA fragments (long DNA) in feces. In the present study, the sensitivity and specificity of fecal-based long DNA assays were evaluated for the detection of colorectal cancer (CRC). Feces were collected from 54 healthy volunteers and 130 patients with CRC prior to surgical treatment. The presence of long DNA of the adenomatosis polyposis coli, Kirsten rat sarcoma viral oncogene homolog (KRAS), B-raf proto-oncogene, serine/threonine kinase and p53 genes was assessed by polymerase chain reaction followed by electrophoresis. The identification of long DNA in feces was found to exhibit a sensitivity of 56.2% and specificity of 96.3% for CRC detection. In addition, long DNA was identified in the feces of 58/90 (64.4%) patients with distal CRC and 15/40 (37.5%) patients with proximal CRC. This study indicates the potential of the fecal long DNA assay as a non-invasive and easily performed method for the detection of individuals with CRC.

Highlights

Colorectal cancer (CRC) is the fourth leading cause of cancer‐associated mortality in males and the third leading cause in females worldwide [1]
The main approach used for CRC screening worldwide is the fecal occult blood test (FOBT) [3]
adenomatosis polyposis coli (APC) long DNA was identified in the feces of 60/130 (46.2%) patients with CRC and 1/54 (1.9%) of the controls (P

Summary

Introduction

Colorectal cancer (CRC) is the fourth leading cause of cancer‐associated mortality in males and the third leading cause in females worldwide [1]. As >95% of patients with CRC would benefit from curative surgery if diagnosed at an earlier or precancerous stage [2], it is important to develop highly sensitive and specific assays to detect CRC earlier, which are non‐invasive, inexpensive and easy to perform. The main approach used for CRC screening worldwide is the fecal occult blood test (FOBT) [3]. To avoid the disadvantages of the FOBT, more sensitive and specific screening methods are required

Methods

Results

Conclusion